Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fexofenadine + montelukast is a fixed-dose combination of two small molecule drugs used primarily for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Fexofenadine is a second-generation antihistamine that acts as an antagonist at the histamine H1 receptor, thereby reducing symptoms like sneezing, itching, runny nose, and watery eyes. Montelukast is a leukotriene receptor antagonist that blocks leukotriene D4 at the cysteinyl leukotriene receptor in the lungs and bronchial tubes; this action reduces inflammation, mucus production, airway narrowing, and other allergy-related symptoms. The combination provides broader symptom control than either agent alone and may be particularly useful in patients with both upper respiratory allergies and mild asthma or those not adequately controlled on monotherapy[3][4][5][8]. It has also been studied for use in prurigo nodularis resistant to conventional therapy[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fexofenadine + montelukast.